Correlation Between Adaptimmune Therapeutics and Intracellular

Can any of the company-specific risk be diversified away by investing in both Adaptimmune Therapeutics and Intracellular at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Adaptimmune Therapeutics and Intracellular into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Adaptimmune Therapeutics Plc and Intracellular Th, you can compare the effects of market volatilities on Adaptimmune Therapeutics and Intracellular and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Adaptimmune Therapeutics with a short position of Intracellular. Check out your portfolio center. Please also check ongoing floating volatility patterns of Adaptimmune Therapeutics and Intracellular.

Diversification Opportunities for Adaptimmune Therapeutics and Intracellular

-0.44

Correlation Coefficient

Adaptimmune Therapeutics  Intracellular

Very good diversification

The 3 months correlation between Adaptimmune and Intracellular is -0.44. Overlapping area represents the amount of risk that can be diversified away by holding Adaptimmune Therapeutics Plc and Intracellular Th in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Intracellular Th and Adaptimmune Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Adaptimmune Therapeutics Plc are associated (or correlated) with Intracellular. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Intracellular Th has no effect on the direction of Adaptimmune Therapeutics i.e., Adaptimmune Therapeutics and Intracellular go up and down completely randomly.

Pair Corralation between Adaptimmune Therapeutics and Intracellular

Given the investment horizon of 90 days Adaptimmune Therapeutics Plc is expected to under-perform the Intracellular. But the stock apears to be less risky and, when comparing its historical volatility, Adaptimmune Therapeutics Plc is 1.45 times less risky than Intracellular. The stock trades about -0.08 of its potential returns per unit of risk. The Intracellular Th is currently generating about 0.16 of returns per unit of risk over similar time horizon. If you would invest  8,565  in Intracellular Th on November 28, 2024 and sell it today you would earn a total of  4,272  from holding Intracellular Th or generate 49.88% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Adaptimmune Therapeutics Plc  vs.  Intracellular Th

Adaptimmune Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Intracellular Th

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Intracellular Th are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite fairly uncertain fundamental indicators, Intracellular demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Adaptimmune Therapeutics and Intracellular

The main advantage of trading using opposite Adaptimmune Therapeutics and Intracellular positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Adaptimmune Therapeutics position performs unexpectedly, Intracellular can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Intracellular will offset losses from the drop in Intracellular's long position.

The idea behind Adaptimmune Therapeutics Plc and Intracellular Th pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.